iTeos Therapeutics (ITOS) Notified for Nasdaq Delisting via Form 25

Rhea-AI Filing Summary

Nasdaq has submitted a Form 25 notifying the SEC of the removal of iTeos Therapeutics, Inc. (ITOS) from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies the issuer's principal office at 321 Arsenal Street, Watertown, Massachusetts and provides a contact phone number. The form states the Exchange and the issuer have complied with applicable rule provisions governing withdrawal or removal, but the specific rule selection box, signature and date fields are not completed in the provided content.

Positive

• Exchange and issuer compliance language is included indicating adherence to referenced procedural rules

Negative

• Notice of removal/delisting of iTeos Therapeutics (ITOS) from Nasdaq is indicated, which is material to shareholders
• Signature, date, and specific rule-selection fields are not completed in the provided content, limiting confirmation of execution and timing

Insights

Securities Listing Specialist

TL;DR: Nasdaq filed to remove ITOS from listing; the form indicates procedural compliance but lacks signature/date.

The filing is a formal notification that Nasdaq seeks removal of iTeos Therapeutics' securities from the exchange and asserts compliance with the procedural requirements of the Exchange Act rules referenced. The document includes issuer identification and exchange name but omits which specific subsection was checked and omits the signing party and date. From a listings-compliance perspective, the filing meets the requirement to notify the SEC, yet the absence of a completed signature block and explicit rule selection in the provided text limits confirmation of whether the removal is voluntary or initiated by the Exchange.

Corporate Governance Analyst

TL;DR: The notice signals delisting/withdrawal action for ITOS; procedural language is present but key execution details are missing in the excerpt.

The document shows Nasdaq certifying it has reasonable grounds to file Form 25 for iTeos Therapeutics and references compliance with rules governing withdrawal/removal. For governance review, the filing is material because removal from an exchange affects shareholder liquidity and reporting status. However, the provided content lacks the executed signature and date and does not specify the precise rule provision selected, which constrains assessment of timing and voluntariness.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-39401

Issuer:	iTeos Therapeutics, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	321 Arsenal Street
	Watertown	MASSACHUSETTS	02142
Telephone number:					857-204-4583

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-08-29	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What action does this Form 25 notify for iTeos Therapeutics (ITOS)?

The form notifies the SEC of the removal of iTeos Therapeutics' securities from listing and/or registration on Nasdaq.

Does the filing state whether the removal is voluntary or initiated by Nasdaq?

The provided content does not specify whether the removal is voluntary or initiated by the Exchange; it only cites compliance with withdrawal/removal rules.

What issuer contact information is included for ITOS in the filing?

The filing lists the issuer address as 321 Arsenal Street, Watertown, Massachusetts 02142 and telephone number 857-204-4583.

Are the rule provisions that support the removal identified in the form?

The form displays the referenced rule provisions but the provided excerpt does not show which specific rule box was selected.

Is there a signed and dated certification in the provided content?

No. The signature block and date fields are not completed in the supplied excerpt.